Indication:
Peritoneal /Pleural effusions caused by metastatic cancer
Adverse Reaction:
Common adverse reactions-
Transitory radiation sickness, bone marrow depression , pleuritis, peritonitis, nausea,
abdominal cramps,
Radiation damage may occur if accidentaly injected interstitially or into a loculation.
Contra-Indications:
Chromic phosphate P 32 should be used in the presence of ulerative tumors.
Administration should not be made in exposed cavites.or there is evidence of loculation,
unless the extent of loculation is determined.
Special precautions/warnings
Chromic phosphate P32 is for intravascular use.
Interactivity installation - careful intracavitary instillation is required to avoid placing the dose of chromic phosphate P 32 into intrpleural or intraperitonal loculations, bowel lumen or into the body wall
Interstinal fibrosis of necrosis and chronic fibrosis of the body wall have been reported.
Pregnancy- should not be administered to patients who are pregnant , unless the benefits
outweigh the risks.
Lactation- should not be administered to patients who are experiencing lactation unless the benefits ouweigh the risks.
Children - safety and efficacy in pediatric patients not established.
Dosages/ Overdosage Etc:
Indication-
Peritoneal /Pleural effusions caused by metastatic cancer
Dosage
Suggested dosage emolyed in average patient 70kg is -
Intraperitoneal instillation - 370 to 740 mBq ( 10 to mCi )
Intrapleural instillation- 222 to 444 mBq ( 6 to 12mCi )
Doses for interstitial use should be based on estimated gram weight of tumor about
3.7 to 18 MBq /g ( 0.1 to 0.5 mCi )
The patient dose should be measured by a suitable radioactivity calibration system
immediately prior to administration
Patient Information:
Chromic Phosphate P 32- Therapeutic
1.Pregnancy-
Radiopharmaceuticals are usually not recommended for use during pregnancy,
to avoid exposing the fetus to radiation . However, some treatment using
radiopharmaceuticals may be required even during pregnancy . Be sure you
have discussed this with your doctor.
2. Breast-feeding-
Chromic phosphate P 32 passes into breast milk. If you must receive this
radiopharmaceutical, it may be necessary for you to stop breast-feeding
during treatment. Be sure you have discussed this with your doctor.
3.Children-
There is no specific information comparing chromic phosphate P 32 in children
with use in other age groups.
4.Older adults-
Many medicines have not been studied specifically in older people. Therefore,
it may not be known whether they work exactly the same way they do in
younger adults.
Although there is no specific information comparing use of chromic phsphate P 32
in the elderly with use in other age groups, this medicine is not expected to cause
or if they cause different side effects or problems in older people than it does in
younger adults.
Pregnancy and lactation:
Pregnancy-
Should not be administered to patients who are pregnant , unless the benefits
outweigh the risks.
Lactation-
Should notbe administered to patients who are experiencing lactation unless the
benefits ouweigh the risks.
Children -
Safety and efficacy in pediatric patients not established.
Manufacturer Details